neuropeptide-y and Immune-System-Diseases

neuropeptide-y has been researched along with Immune-System-Diseases* in 3 studies

Reviews

3 review(s) available for neuropeptide-y and Immune-System-Diseases

ArticleYear
NPY and receptors in immune and inflammatory diseases.
    Current topics in medicinal chemistry, 2007, Volume: 7, Issue:17

    Growing evidence suggests that neuropeptide Y (NPY) plays an important role in the immune system. NPY is produced by the central and peripheral nervous system but also by immune cells in response to activation. NPY has pleiotropic effects on both the innate and adaptive arms of the immune system, with effects ranging from the modulation of cell migration to macrophage, T helper (Th) cell cytokine release, and antibody production. Subsequent studies have confirmed the importance of this system in immunity in particular via the demonstration that Y1, a receptor for NPY, plays a fundamental role in autoimmunity and inflammation using Y1-deficient animals. Furthermore, clinical studies have suggested a role for NPY in other immune disorders such as asthma and arthritis. This review provides the latest information on the role of NPY and Y1 in the immune system, and discusses the potential new opportunities of this work for the development of a new generation of immuno-modulatory treatments of autoimmune and inflammatory diseases.

    Topics: Animals; Autoimmunity; Humans; Immune System Diseases; Inflammation; Neuropeptide Y; Receptors, Neuropeptide Y

2007
The Flinders Sensitive Line rat: a selectively bred putative animal model of depression.
    Neuroscience and biobehavioral reviews, 2005, Volume: 29, Issue:4-5

    The Flinders Sensitive Line (FSL) rats were originally selectively bred for increased responses to an anticholinesterase agent. The FSL rat partially resembles depressed individuals because it exhibits reduced appetite and psychomotor function but exhibits normal hedonic responses and cognitive function. The FSL rat also exhibits sleep and immune abnormalities that are observed in depressed individuals. Neurochemical and/or pharmacological evidence suggests that the FSL rat exhibits changes consistent with the cholinergic, serotonergic, dopaminergic, NPY, and circadian rhythm models but not the noradrenergic, HPA axis or GABAergic models of depression. However, evidence for the genetic basis of these changes is lacking and it remains to be determined which, if any, of the neurochemical changes are primary to the behavioral alterations. The FSL rat model has been very useful as a screen for antidepressants because known antidepressants reduced swim test immobility when given chronically and psychomotor stimulants did not. Furthermore, rolipram and a melatonin agonist were shown to have anti-immobility effects in the FSL rats and later to have antidepressant effects in humans. Thus, the FSL rat model of depression exhibits some behavioral, neurochemical, and pharmacological features that have been reported in depressed individuals and has been very effective in detecting antidepressants.

    Topics: Animals; Antidepressive Agents; Anxiety; Asthma; Behavioral Symptoms; Breeding; Circadian Rhythm; Depression; Disease Models, Animal; Humans; Hypothalamo-Hypophyseal System; Immune System Diseases; Irritable Bowel Syndrome; Nerve Growth Factors; Neuropeptide Y; Neurotransmitter Agents; Pituitary-Adrenal System; Rats; Rats, Inbred Strains

2005
Relevance of neuropeptide Y for the neuroimmune crosstalk.
    Journal of neuroimmunology, 2003, Volume: 134, Issue:1-2

    Both cellular and humoral functions of the immune system are modulated by the sympathetic nervous system (SNS). This interaction is mainly mediated by the release of catecholamines (CA) and their receptor-specific action on immune cells. However, neuropeptide Y (NPY), also present in sympathetic nerve terminals, is released upon SNS-stimulation. NPY modulates potent immunological effects in vitro and in vivo, such as differentiation of T helper cells, monocyte mediator release, NK cell activation, and immune cell redistribution. In addition to this direct action within the neuroimmune crosstalk, NPY is also able to modulate the immunomodulatory effects of other neurotransmitters, thereby acting as a neuroimmune co-transmitter. This review will discuss key findings from recent studies, provide implications for the clinical situation, and integrate the pleiotropic functions of NPY in the context of neuroimmune interactions.

    Topics: Animals; Catecholamines; Humans; Immune System; Immune System Diseases; Leukocytes; Neuroimmunomodulation; Neuropeptide Y; Neurotransmitter Agents; Signal Transduction; Sympathetic Nervous System

2003